All In Biotech

Drug Trial Radar · NCT04358406

Rhu-pGSN for Severe Covid-19 Pneumonia

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia

Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Jul 30, 2020

Primary completion

May 25, 2021

Study completion Jan 28, 2022

Sponsor

Lead sponsor
BioAegis Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Objectives: Primary * To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5 or 6 on the World Health Organization (WHO) 9-point severity scale * To evaluate the safety and tolerability of three IV doses of rhu-pGSN administered to hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5, or 6 on the WHO 9-point severity scale Secondary * To further assess the efficacy of IV administered rhu-pGSN * To assess changes in WHO 9-point severity score for SOC with or without rhu-pGSN * To evaluate the effect of administered rhu-pGSN on survival rates * To assess the relationship of pGSN levels (and other biomarkers) at baseline with clinical outcomes * \[OPTIONAL\] To follow the pharmacokinetics (PK) of administered rhu-pGSN Immunogenicity • To investigate the development of antibodies against rhu-pGSN post-treatment

Conditions

  • Sars-CoV2

Interventions

  • Recombinant human plasma gelsolin (Rhu-pGSN)Drug

    Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses

  • PlaceboOther

    Normal saline in matched volume to treatment arm. Undistinguishable in syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or DialysisTime frame: Day 14
  2. Safety: Number of Subjects With SAEsTime frame: Day 1 through Day 90

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie

    Timișoara, Romania

  • Sant Joan de Reus SAM University Hospital

    Reus, Spain

  • Hospital Universitari de Tarragona Joan XXIII

    Tarragona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.